Oxaliplatin
Oxaliplatin (oxaliplatin) is a small molecule pharmaceutical. Oxaliplatin was first approved as Eloxatin on 2002-08-09. It is used to treat colorectal neoplasms, ovarian neoplasms, testicular neoplasms, and urinary bladder neoplasms in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Oxaliplatin (discontinued: Eloxatin, Oxaliplatin)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| oxaliplatin | ANDA | 2026-01-14 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9263 | Injection, oxaliplatin, 0.5 mg |
Clinical
Clinical Trials
3243 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 6 | 2 | — | — | 7 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | 2 | — | — | 4 |
| Colorectal neoplasms | D015179 | — | — | — | 3 | 1 | — | — | 3 |
| Carcinoma | D002277 | — | C80.0 | — | 2 | 1 | — | — | 3 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | 2 | 1 | — | — | 3 |
| Lymphoma | D008223 | — | C85.9 | — | 1 | 1 | — | — | 2 |
| Hodgkin disease | D006689 | — | C81 | — | — | 1 | — | — | 1 |
| Rectal neoplasms | D012004 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adenocarcinoma | D000230 | — | — | — | 2 | — | — | — | 2 |
| Recurrence | D012008 | — | — | — | 1 | — | — | — | 1 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 1 | — | — | — | 1 |
| B-cell lymphoma | D016393 | — | — | — | 1 | — | — | — | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 1 | — | — | — | 1 |
| Neoadjuvant therapy | D020360 | — | — | — | 1 | — | — | — | 1 |
| Cholangiocarcinoma | D018281 | — | C22.1 | — | 1 | — | — | — | 1 |
| Biliary tract neoplasms | D001661 | — | C24.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Esophageal neoplasms | D004938 | — | C15 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Oxaliplatin |
| INN | oxaliplatin |
| Description | Oxaliplatin, sold under the brand name Eloxatin among others, is a cancer medication (platinum-based antineoplastic class) used to treat colorectal cancer. It is given by injection into a vein.
|
| Classification | Small molecule |
| Drug class | antineoplastics (platinum derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 61825-94-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL414804 |
| ChEBI ID | — |
| PubChem CID | 11947679 |
| DrugBank | DB00526 |
| UNII ID | 04ZR38536J (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
Black-box warning for: Oxaliplatin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
77,798 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use